Podcast appearances and mentions of David R Liu

This podcast is a commentary and does not contain any copyrighted material of the reference source. We strongly recommend accessing/buying the reference source at the same time. ■Reference Source https://www.ted.com/talks/david_r_liu_can_we_cure_genetic_diseases_by_rewriting_dna ■Post on this topic (You can get FREE learning materials!) https://englist.me/174-academic-words-reference-from-david-r-liu-can-we-cure-genetic-diseases-by-rewriting-dna-ted-talk/ ■Youtube Video https://youtu.be/fZgsEKAWWTw (All Words) https://youtu.be/Cq7aCmkte_w (Advanced Words) https://youtu.be/qHfrjBS8hxQ (Quick Look) ■Top Page for Further Materials https://englist.me/ ■SNS (Please follow!)

Dr. David R. Liu is the Richard Merkin Professor and Director of the Merkin Institute of Transformative Technologies in Healthcare, vice-chair of the faculty at the Broad Institute of MIT and Harvard, the Thomas Dudley Cabot Professor of the Natural Sciences at Harvard University, and a Howard Hughes Medical Institute (HHMI) investigator. In addition, he is the founder or co-founder of several biotechnology and therapeutics companies, including Beam Therapeutics, Prime Medicine, Editas Medicine, Pairwise Plants, Exo Therapeutics, Chroma Medicine, Resonance Medicine, and Nvelop Therapeutics. David's research integrates components of biological evolution with chemistry to enable the development of new types of therapeutics and to better study biology. Through chemistry, they can change the structure of a molecule in order to change its function in anticipated ways. They also harness the power of cycles of natural selection to evolve molecules with desired tailor-made properties. Outside of science, David's hobbies include photography, making wooden vessels using a wood lathe, growing bonsai trees, and exploring electronic art and other homemade art projects. He enjoys blending creativity and intellectual pursuits to create something surprising and beautiful. He completed his undergraduate education at Harvard College, majoring in chemistry. He was awarded his PhD in organic chemistry from UC Berkeley, and he joined the faculty at Harvard University afterwards. He has been an HHMI investigator since 2005. Over the course of his career, David has received numerous awards and accolades, including being named the 2022 King Faisal Prize Laureate in Medicine and receipt of the Ronald Breslow Award for Biomimetic Chemistry, the American Chemical Society David Perlman Award, ACS Chemical Biology Award, the American Chemical Society Pure Chemistry Award, the Arthur Cope Young Scholar Award, and other prestigious awards for his research and teaching. In 2016 and 2020, he was named one of the Top 20 Translational Researchers in the world by Nature Biotechnology, and he was named one of Nature's 10 researchers in 2022. In addition, he is an elected Member of the U.S. National Academy of Sciences, the U.S. National Academy of Medicine, and the American Association for the Advancement of Science. In this interview, David shares more about his life and science.

Beverly Mok is a graduate student in Chemistry and Chemical Biology at Harvard University. She is currently working in the complex field of genes and genomics focusing on genome editing in the David Liu Lab. She is also involved in the development of programmable tools to perform detailed and accurate modifications on the human genome. Current tools do a double-stranded break which the cell may try to resolve in a way that may not be ideal. Once the break happens, the cells resolve the break in two ways. They make repairs by insertions or deletions which is not ideal. Or they supply a template DNA that undergoes homogenous DNA repair back to the original sequence to precisely repair the DNA. Base editing is a new way of targeting and repairing faulty genes. The new genome editing techniques do not use double-strand breaks. The benefits of the base editing approach is that it facilitates precise genome editing and minimizes undesired by-products and toxicity associated with the double-strand breaks in DNA. Click on play to learn about: How CRISPR-Cas9 is used to edit parts of the genome. A new process of base editing that does not introduce double-strand breaks. How the new process achieves exquisite levels of specificity with base editing. What genetic diseases are being considered for future studies involving base editing. Mok is participating in studies to identify possible next generation biotherapeutics and genome editing techniques that have the potential to treat and possibly cure genetic diseases like Huntington's disease, blood cancers, and cystic fibrosis. She applies chemical biology strategies to genome editing to advance the capabilities and safety of genome-engineering proteins. To learn more visit: https://liugroup.us David R. Liu @davidrliu liugroup @liugroup Episode also available on Apple Podcasts: apple.co/30PvU9C

The architect of base editing and prime editing, Harvard University chemist David R. Liu, recalls the genesis of the technology and discusses exciting preclinical results and potential future applications. {Sponsored by Pegasus Books}

同じ細胞から異なるタイミングでトランスクリプトームを複数計測できる技術Live-seqの原著論文を読みました。Show notes Genome-wide molecular recording using Live-seq BioRxiv 2021 … 今回紹介した論文。 NeuroRadio … 本格派の神経科学研究者系ポッドキャスト Rebuild Misreading Chat CSの論文読んで話をしよう サンキュータツオ 予備校のノリで学ぶ「大学の数学・物理」 (YouTube) PNE … 蛋白質核酸酵素 新着論文レビュー Manolis Kellis (YouTube) … Manolis KellisのYoutubeチャンネル。MITでの講義動画が盛りだくさん。 iBology Conversations in Genetics: Leland Hartwell (Cell Cycle Control in Yeast) Conversations in Genetics: Matthew Meselson (DNA Replication, Recombination and Repair) Conversations in Genetics: Sydney Brenner (Genetic Code, Worm Development) Conversations in Genetics: Elizabeth Blackburn (Telomeres, Cancer, Aging) Future of CRISPR (base & prime) and epigenome editing (Interview with Prof David R. Liu) Transcriptional recording by CRISPR spacer acquisition from RNA. Nature 2018 … Record-seqについての原著論文。 9. One-shot beautiful experiment … ゲノム編集を利用した情報の記録について話した回。 Editorial notes 雑談ばっかりにならないよう論文もどんどん読んでいきます (soh) 桜咲きました。いうて、研究者の方がやっているYouTubeもちらほらありますよね。(tadasu)

In a story of scientific discovery, chemical biologist David R. Liu shares a breakthrough: his lab's development of base editors that can rewrite DNA. This crucial step in genome editing takes the promise of CRISPR to the next level: if CRISPR proteins are molecular scissors, programmed to cut specific DNA sequences, then base editors are pencils, capable of directly rewriting one DNA letter into another. Learn more about how these molecular machines work -- and their potential to treat or even cure genetic diseases. Hosted on Acast. See acast.com/privacy for more information.

In a story of scientific discovery, chemical biologist David R. Liu shares a breakthrough: his lab's development of base editors that can rewrite DNA. This crucial step in genome editing takes the promise of CRISPR to the next level: if CRISPR proteins are molecular scissors, programmed to cut specific DNA sequences, then base editors are pencils, capable of directly rewriting one DNA letter into another. Learn more about how these molecular machines work -- and their potential to treat or even cure genetic diseases.

Der Chemiker und Biologe David R. Liu präsentiert einen Durchbruch in der Geschichte der wissenschaftlichen Entdeckungen: Sein Labor entwickelte Basen-Editoren, die DNS umschreiben können. Dieser entscheidende Schritt in der Genom-Editierung hebt die Versprechungen von CRISPR auf ein neues Level. Wenn CRISPR-Proteine molekulare Scheren sind, die programmierbar bestimmte DNS-Sequenzen schneiden, dann sind Basen-Editoren Stifte, die direkt eine DNS-Base in eine andere umschreiben können. Lernen Sie mehr darüber, wie diese molekularen Maschinen funktionieren und über ihr Potenzial genetische Erkrankungen erfolgreich zu behandeln oder sogar zu heilen.

생화학자인 데이비드 알 류가 획기적인 과학적 발견에 대하여 강연합니다. 그의 팀은 DNA를 수정할 수 있는 염기편집기를 개발하였습니다. 유전자 편집 과정에서 중요한 이 단계는 크리스퍼의 꿈을 다음 단계로 끌어올리는 것입니다. 크리스퍼 단백질을 특정 DNA 구조를 자를 수 있는 분자 가위라고 한다면 염기 편집기는 DNA 성분 하나 하나를 수정할 수 있는 연필에 비유할 수 있습니다. 이들 분자 기계들이 어떻게 작동하는지, 그리고 유전질환을 치료하는 분야에서 발휘할 잠재력에 대해서 더 알아보시기 바랍니다.

El biólogo químico David R. Liu comparte con nosotros la historia del descubrimiento científico realizado en su laboratorio: el desarrollo de editores de bases que pueden reescribir el ADN. Este paso crucial en la edición del genoma lleva la promesa de CRISPR al siguiente nivel: si las proteínas de CRISPR pueden considerarse tijeras moleculares programadas para cortar secuencias de ADN, los editores de bases pueden considerarse lápices capaces de reescribir las letras del ADN. En esta charla, David. R. Liu explica cómo estas máquinas moleculares funcionan y cuál es su potencial para tratar e incluso curar enfermedades genéticas.

Em uma história de descoberta científica, o biólogo químico David R. Liu compartilha um avanço importante: o desenvolvimento, pelo laboratório dele, de editores de base capazes de reescrever o DNA. Esse passo decisivo na edição do genoma leva a promessa de CRISPR ao próximo nível: se as proteínas CRISPR são tesouras moleculares, programadas para cortar sequências específicas de DNA, então editores de base são lápis, capazes de reescrever diretamente uma letra de DNA em outra. Saiba mais sobre como essas máquinas moleculares funcionam e o potencial delas para tratar ou até mesmo curar doenças genéticas.

A travers le récit d'une découverte scientifique, le biologiste et chimiste David R. Liu partage une avancée capitale : le développement par son laboratoire de correcteurs génomiques capables de réécrire l'ADN. Cette étape cruciale de la correction génomique porte la promesse de CRISPR à un niveau supérieur : si les protéines de CRISPR sont des ciseaux moléculaires, programmés pour couper des séquences d'ADN spécifiques, les correcteurs génomiques sont des crayons, capables de réécrire directement une lettre d'ADN en une autre. Apprenez-en plus sur le fonctionnement de ces nanomachines et sur leur potentiel pour traiter, voire guérir, les maladies génétiques.

On episode 52 we welcome Kevin Esvelt, Director of the MIT Media Lab Sculpting Evolution group.  At the Media Lab, Esvelt and his world class team of geneticists & biologists invent new ways to study and influence the evolution of ecosystems. By carefully developing and testing these methods with openness and humility, the group seeks to address difficult ecological problems to benefit humanity & the natural world. Prior to joining the MIT Media Lab, Esvelt wove many different areas of science into novel approaches to ecological engineering. He invented phage-assisted continuous evolution (PACE), a synthetic microbial ecosystem for rapidly evolving biomolecules, in the laboratory of David R. Liu at Harvard University. At the Wyss Institute, he worked with George Church to develop the CRISPR system for genome engineering & regulation, and he began the use of bacteriophages and conjugation to engineer microbial ecosystems. Esvelt is credited as the first to describe how CRISPR gene drives could be used to alter the traits of wild populations in an evolutionarily stable manner. And recently, he and his Sculpting Evolution group devised a new form of technology, called ‘daisy drives’, which lets communities aiming to prevent disease alter wild organisms in local ecosystems. Esvelt offers some of the clearest descriptions of GMOs;  CRISPR gene editing; a scientist's role as God while wielding the power of modern tech - and, what we do about that as a society - during our hour 1-hour discussion. Whether you're interested in Genetic Engineering or Fitness Landscapes defining evolutionary biology - this episode will spark your interest.   I was just happy just to be along for the ride.   www.SourcingMatters.show